Scientists found that in a preclinical model, two FDA–approved flu antivirals generally did not successfully treat severe H5N1 infections. Meanwhile, the route of infection, whether through the eye, the nose or the mouth, significantly impacts effectiveness.
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.